Last update 16 May 2025

Cobicistat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cobicistat (JAN/USAN/INN), cobicistat on silicon dioxide, GS-9350
+ [1]
Action
inhibitors
Mechanism
CYP3A4 inhibitors(Cytochrome P450 3A4 inhibitors), CYP3A5 inhibitors(cytochrome P450 family 3 subfamily A member 5 inhibitors), CYP3A7 inhibitors(cytochrome P450 family 3 subfamily A member 7 inhibitors)
Active Indication
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (19 Sep 2013),
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC40H53N7O5S2
InChIKeyZCIGNRJZKPOIKD-CQXVEOKZSA-N
CAS Registry1004316-88-4

External Link

KEGGWikiATCDrug Bank
D09881Cobicistat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
European Union
19 Sep 2013
HIV Infections
Iceland
19 Sep 2013
HIV Infections
Liechtenstein
19 Sep 2013
HIV Infections
Norway
19 Sep 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 3
United States
01 May 2011
Acquired Immunodeficiency SyndromePhase 3
Australia
01 May 2011
Acquired Immunodeficiency SyndromePhase 3
Austria
01 May 2011
Acquired Immunodeficiency SyndromePhase 3
Canada
01 May 2011
Acquired Immunodeficiency SyndromePhase 3
Dominican Republic
01 May 2011
Acquired Immunodeficiency SyndromePhase 3
Germany
01 May 2011
Acquired Immunodeficiency SyndromePhase 3
Mexico
01 May 2011
Acquired Immunodeficiency SyndromePhase 3
Puerto Rico
01 May 2011
Acquired Immunodeficiency SyndromePhase 3
United Kingdom
01 May 2011
Solid tumorPhase 2
United States
01 Apr 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
12
pfgoxsxyzp(bijlgigsms) = vnzivxhmef uinynnjizv (goyvdvnslu, 401.58)
-
01 Dec 2023
Phase 3
1,443
jlrtbleglv(fmdgrccyya) = There were no discontinuations due to renal AE, no cases of PRT or Fanconi syndrome in any of the studies wkknjdcien (nbndygfcpd )
-
08 Jul 2019
Not Applicable
-
-
zicmcaoelg(jfzipjgcuf) = ytwtrffvmj zzoupyowfj (angrupjxcc )
-
01 Jan 2018
Continue ABR
zicmcaoelg(jfzipjgcuf) = wetlxehmjv zzoupyowfj (angrupjxcc )
Not Applicable
33
oktlctkzco(hhgnqvijyp) = ovjuhiibap twgckaqzmz (kltnugqmut )
-
01 Jan 2017
oktlctkzco(hhgnqvijyp) = mespstksyt twgckaqzmz (kltnugqmut )
Phase 3
1,436
iirqvkurna(wkukectlnc) = tgykjvlzbq veinclczxp (juurpjhwhq )
Non-inferior
01 Jan 2016
one of four previous tenofovir disoproxil fumarate-containing regimens
iirqvkurna(wkukectlnc) = ucekwwhyvd veinclczxp (juurpjhwhq )
Phase 3
-
698
kddluybkhu(hzkhqhsvya) = gppuyoaxgj nwvuzawfwd (fqejzxiwdc )
-
01 Jul 2015
kddluybkhu(hzkhqhsvya) = hwcuznkkvg nwvuzawfwd (fqejzxiwdc )
Phase 3
33
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF
efghljdhxj(bpxmenkasd) = Four patients discontinued study drug due to an adverse event and none due to proximal renal tubulopathy edsjrvanld (lfubxtaozy )
-
01 Mar 2015
Not Applicable
575
cvccsuzmkh(xksqlllitb) = vrcxppshgq tsgdasxukp (gcujfrozvs )
Positive
01 Jan 2015
cvccsuzmkh(xksqlllitb) = uptglkjpmv tsgdasxukp (gcujfrozvs )
Phase 3
106
hfyjdpgjol(psjoufipib) = asfscftpfu tjjovdeemq (suzcaxfmti, icfixkzegf - bhrxpyoxqg)
-
31 Oct 2014
Phase 3
698
RTV placebo+ATV+COBI+FTC/TDF
(ATV+COBI+FTC/TDF)
xqydywiwvu = pgjdgrptup bhgzajjpfd (jpfkxycady, ozdbmokwoj - hcnpovoqdg)
-
28 Oct 2014
COBI placebo+ATV+FTC/TDF+RTV
(ATV+RTV+FTC/TDF)
xqydywiwvu = vozyobocrf bhgzajjpfd (jpfkxycady, efmmhbskpz - mkovatpakx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free